Fig. 9

Impact of chronic severe thrombocytopenia on the inflammatory and immune profiles of B16F1 and AT-3 tumors. A-B. Comparative heatmap of tumor cytokines and angiogenic factors expressed in (A) B16F1 and (B) AT-3 tumor extracts from control mice and mice with chronic severe thrombocytopenia mice using Proteome Profiler arrays (n = 4 tumors per group, p < 0.05). C. Comparison of myeloperoxidase (MPO) levels used as a marker of neutrophil infiltration in B16F1 and AT-3 tumor extracts from control mice and mice with chronic severe thrombocytopenia. n = 25 (100%) and 22 (< 10%) B16F1 tumors; n = 24 (100%) and 29 (< 10%) AT-3 tumors. D. Quantification of CD45-positive cells in B16F1 and AT-3 tumors from control mice and mice with chronic severe thrombocytopenia. n = 9 (100%) and 10 (< 10%) different B16F1 tumors; and n = 9 (100%) and 8 (< 10%) different AT-3 tumors. E. Comparison of cytotoxic cell infiltration among control mice and mice with chronic severe thrombocytopenia in B16F1 and AT-3 tumors by measurement of their granzyme B content. n = 25 (100%) and 22 (< 10%) different B16F1 tumors; and n = 20 (100%) and 30 (< 10%) different AT-3 tumors. ns: non-significant